Morgan Stanley’s Akari Therapeutics AKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5 | Buy |
+1
| New | +$9 | ﹤0.01% | 8233 |
|
|
2025
Q4 | – | Hold |
0
| – | – | – | 8187 |
|
|
2025
Q3 | – | Hold |
0
| – | – | – | 8138 |
|
|
2025
Q2 | – | Hold |
0
| – | – | – | 8052 |
|
|
2025
Q1 | – | Hold |
0
| – | – | – | 8019 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 7919 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 7783 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 7755 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7756 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 7656 |
|
|
2022
Q2 | – | Sell |
-7
| Closed | -$7K | – | 7786 |
|
|
2022
Q1 | $7K | Hold |
7
| – | – | ﹤0.01% | 7491 |
|
|
2021
Q4 | $8K | Hold |
7
| – | – | ﹤0.01% | 7522 |
|
|
2021
Q3 | $9K | Sell |
7
-1
| -13% | -$1.36K | ﹤0.01% | 7355 |
|
|
2021
Q2 | $11K | Buy |
8
+1
| +14% | +$1.6K | ﹤0.01% | 7201 |
|
|
2021
Q1 | $15K | Hold |
7
| – | – | ﹤0.01% | 6818 |
|
|
2020
Q4 | $11K | Hold |
7
| – | – | ﹤0.01% | 6599 |
|
|
2020
Q3 | $10K | Buy |
7
+6
| +600% | +$8.9K | ﹤0.01% | 6266 |
|
|
2020
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 6431 |
|
|
2020
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 6445 |
|
|
2019
Q4 | $2K | Sell |
1
-1
| -50% | -$1.47K | ﹤0.01% | 6489 |
|
|
2019
Q3 | $2K | Buy |
2
+1
| +100% | +$1.53K | ﹤0.01% | 6464 |
|
|
2019
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 6449 |
|
|
2019
Q1 | $4K | Buy |
+1
| New | +$1.91K | ﹤0.01% | 6349 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6586 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6608 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6654 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6599 |
|
|
2017
Q4 | – | Sell |
-11
| Closed | -$42.4K | – | 6476 |
|
|
2017
Q3 | $54K | Buy |
+11
| New | +$41.2K | ﹤0.01% | 5757 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6494 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6414 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6374 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6357 |
|
|
2016
Q2 | – | Sell |
-2
| Closed | -$25.8K | – | 6210 |
|
|
2016
Q1 | $18K | Buy |
+2
| New | +$20.7K | ﹤0.01% | 5944 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6599 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6633 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6540 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6556 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6559 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6505 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 6463 |
|
Other funds holding AKTX
AC
CAM
IA
SS
TC
Morgan Stanley's AKTX Position: Q1 2026 in Review
Morgan Stanley opened a new position in Akari Therapeutics (AKTX) in Q1 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #8233 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in AKTX as recently as Q1 2022.
Morgan Stanley first reported a position in AKTX in Q1 2016 and has held it in 16 quarters since. The position peaked at $54K in Q3 2017. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.
- Morgan Stanley held 1 share of Akari Therapeutics worth $5 as of Q1 2026.
- Akari Therapeutics was a new Morgan Stanley position in Q1 2026.
- Akari Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8233 holding.
- Morgan Stanley first reported a position in Akari Therapeutics in Q1 2016 and has held it in 16 quarters since.
- Morgan Stanley's Akari Therapeutics position peaked at $54K in Q3 2017.
- 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.